REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory Payment Classification (APC) for the HeartFlow® FFRct Analysis, a first-of-its-kind non-invasive technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD). Under the APC payment system, […]
Coronary/Structural Heart
ABBOTT’S MITRACLIP APPROVED AS FIRST TRANSCATHETER MITRAL VALVE REPAIR DEVICE IN JAPAN
ABBOTT PARK, Ill., Nov. 6, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the company’s MitraClip device for treatment of people with mitral regurgitation (MR), a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward […]
Neovasc Jumps on FDA Nod for Clinical Trial
VANCOUVER, Nov. 6, 2017 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) announced that it has received approval of the U.S. Food and Drug Administration (“FDA”) to initiate the COSIRA-II IDE pivotal clinical trial. The trial’s purpose will be to demonstrate the safety and effectiveness of the Company’s novel Reducer system […]
Mitralign Release: SCOUT I Study Using Trialign System for Transcatheter Tricuspid Repair Continues to Show Positive Outcomes at 1 Year
DENVER–(BUSINESS WIRE)– Mitralign, Inc.., an innovative developer of transcatheter tricuspid and mitral valve repair solutions, today released 1 year follow up data from the SCOUT I Early Feasibility Study designed to evaluate the performance of its Trialign™ System. The data presented by Rebecca Hahn, M.D., New York-Presbyterian/Columbia University Medical Center, continue […]
Medtronic Evolut(TM) PRO TAVR System with Advanced Sealing Maintains Excellent Outcomes Over Time
DUBLIN and DENVER – November 2, 2017 – Medtronic plc (NYSE:MDT) today presented new data at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting showcasing the excellent clinical performance of the Evolut(TM) Transcatheter Aortic Valve Replacement (TAVR) platform. Six-month data from the newest-generation Evolut PRO System demonstrated continued benefits of its unique valve […]
4C Medical’s Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition
BROOKLYN PARK, Minn., Nov. 2, 2017 /PRNewswire/ — 4C Medical Technologies, Inc., a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) was presented at the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) meeting held October 29-November 2, […]
Medtronic Shows Off Early Intrepid TMVR Data
DUBLIN and DENVER – November 1, 2017 – Medtronic (NYSE:MDT) today presented positive data for its self-expanding Intrepid(TM) transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation. Presented as a First Report Investigation at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting and simultaneously published in the Journal of the American […]
Elixir Medical Corporation Unveils Transformational DynamX™ Stent Featuring Adaptive Segments that Uncage the Stented Artery
MILPITAS, Calif.–(BUSINESS WIRE)– Elixir Medical, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral vascular disease intervention, unveiled for the first time its novel stent technology, DynamXTM, a bioadaptive drug eluting stent (BA-DES) platform at the Transcatheter Cardiovascular Therapeutics […]
TCT 2017: BIOTRONIK Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
Denver, United States / Buelach, Switzerland, 31.10.2017 (PresseBox) – Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market. In addition, clinical and preclinical data presented about Magmaris2 reinforce the case that the magnesium-based resorbable technology does not share the same risk of […]
OrbusNeich’s COMBO Dual Therapy Stent Demonstrates Non-Inferiority vs the Market Leading XIENCE™ Everolimus Eluting Stent
DENVER, October 30, 2017 /PRNewswire/ — New results from the HARMONEE Japan/US Registration Trial, reported by OrbusNeich today in the First Report Investigations session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrate that the COMBO(TM) Dual Therapy Stent (DTS) compares favorably to the market leading option for treating patients […]



